cigb-300 profile

CIGB-300: a synthetic proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

CIGB-300 : A synthetic 25-membered heterodetic cyclic peptide consisting of a 14-membered linear component attached to an 11-membered cyclic portion. A CK2 inhibitor with potential antineoplastic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	86290205
CHEBI ID	83696
MeSH ID	M0526194

Synonym
p15-tat
CHEBI:83696
cigb-300

Excerpt	Reference	Relevance
" The systemic adverse events were rash, facial edema, itching, hot flashes, and localized cramps."	( Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. Acevedo, BE; Alonso, DF; Baladrón, I; Castillo, D; Díaz, A; Gómez, R; González, CA; Herrera, L; López-Saura, P; Perea, SE; Ramos, T; Santana, A; Sigman, H; Solares, AM; Valenzuela, C, 2009)	0.35
"CIGB 300 was safe and well tolerated."	( Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. Acevedo, BE; Alonso, DF; Baladrón, I; Castillo, D; Díaz, A; Gómez, R; González, CA; Herrera, L; López-Saura, P; Perea, SE; Ramos, T; Santana, A; Sigman, H; Solares, AM; Valenzuela, C, 2009)	0.35

Roles (4)

Role	Description
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine.
angiogenesis modulating agent	An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
heterodetic cyclic peptide	A heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond.
polypeptide	A peptide containing ten or more amino acid residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (13.04)	29.6817
2010's	14 (60.87)	24.3611
2020's	6 (26.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (17.39%)	5.53%
Reviews	1 (4.35%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (78.26%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
casein kinase ii Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.	7.45	13	3
cx 4945 [no description available]	2.13	1	0

Condition	Relationship Strength	Studies	Trials
2019 Novel Coronavirus Disease [description not available]	2.31	1	0
Cancer of the Retina [description not available]	2.41	1	0
Cancer of Cervix [description not available]	4.75	3	2
Eye Cancer, Retinoblastoma [description not available]	2.41	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	4.75	3	2
Retinoblastoma A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)	7.41	1	0
Acute Myelogenous Leukemia [description not available]	2.6	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.6	1	0
Carcinoma, Non-Small Cell Lung [description not available]	2.52	2	0
Cancer of Lung [description not available]	3.06	4	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.52	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	3.06	4	0
Breast Cancer [description not available]	7.25	1	0
Invasiveness, Neoplasm [description not available]	2.25	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.25	1	0
Angiogenesis, Pathologic [description not available]	2.83	3	0
Benign Neoplasms [description not available]	4.15	5	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.15	5	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.1	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.1	1	0
Metastase [description not available]	2.15	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.15	1	0
Carcinoma, Small Cell Lung [description not available]	2.05	1	0
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	2.05	1	0
Adverse Drug Event [description not available]	3.43	1	1
Cervix Dysplasia [description not available]	3.43	1	1
Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE.	3.43	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	3.43	1	1

cigb-300

Description

Cross-References

Synonyms (3)

Research Excerpts

Toxicity

Roles (4)

Drug Classes (2)

Research

Studies (23)

Market Indicators

Research Demand Index: 22.34

Study Types

cigb-300

Description

Cross-References

Synonyms (3)

Research Excerpts

Toxicity

Roles (4)

Drug Classes (2)

Research

Studies (23)

Market Indicators

Research Demand Index: 22.34

Study Types

Related Drugs (2)

Related Conditions (28)